Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 5: 941 - 953

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.05.001

Meta-analysises

Efficacy and safety of Compound E’jiao Jiang (复方阿胶浆) for treating leukopenia based: a systematic review and Meta-analysis

  • Zhenkai LU ,
  • Chang TAN ,
  • Yingjie ZHI ,
  • Xuming ZHANG ,
  • Yanming XIE
Expand
  • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received date: 2024-10-26

  Accepted date: 2025-01-14

  Online published: 2025-09-15

Supported by

The Qihuang Scholars Support Program of the National Administration of Traditional Chinese Medicinet: 2021 Qihuang Scholars Support Project(National Chinese Medicine Teaching Letter [2022] 6);National Traditional Medicine Administration's Project for Establishing National Famous and Elderly Traditional Medicine Transmission Workshops: Xie Yanming National Famous Traditional Chinese Medicine Expert Transmission Studio(National Chinese Medicine Education Letter [2022] 75)

Fold

Abstract

OBJECTIVE: To systematically assess the safety and effectiveness of Compound E’jiao Jiang (复方阿胶浆, CEJ) for treating leukopenia.

METHODS: Four English and four Chinese databases were searched for randomized controlled trials (RCTs) on CEJ for treating leukopenia up to July 1, 2024. Two researchers independently screened the studies and extracted necessary data. Methodological quality and risk of bias were assessed using the Cochrane risk-of-bias tool. Articles eligible for Meta-analysis were analyzed using RevMan.

RESULTS: A total of 28 RCTs involving 2041 participants were included, with 1034 in the experimental group and 1007 in the control group. The Meta-analysis showed a significant effect of CEJ in treating leukopenia caused by tumor and immune diseases (three RCTs) [risk ratio (RR) = 1.17, 95% confidence interval (CI) (1.08, 1.27), P= 0.0002, I 2 = 35%]. The combination of CEJ and Western Medicine showed superior results in terms of white blood cell (WBC) counts (fifteen RCTs) [mean difference (MD) = 1.12, 95% CI(0.83, 1.42), P< 0.000 01, I 2 = 88%], Karnofsky Performance Status (KPS) levels (seven RCTs) [RR = 1.39, 95% CI(1.25, 1.55), P <0.000 01, I 2 = 36%], and mitigation of bone marrow toxicity (eleven RCTs) [RR = 0.61, 95% CI(0.54, 0.69), P < 0.00001, I 2 = 24%] compared to Western Medicine alone. Adverse events mainly included gastrointestinal and digestive reactions associated with chemotherapy drugs.

CONCLUSION: CEJ alone or in combination with Western Medicine for treating leukopenia caused by tumor and immune diseases improved WBC counts, clinical efficacy, and quality of life. It also reduced bone marrow toxicity-induced leukopenia, enhanced the efficacy of chemotherapy while reducing its toxicity, and alleviated symptoms. No significant adverse events were reported in the RCTs, indicating favorable efficacy and safety. The Grading of Recommendations Assessment, Development and Evaluation assessment indicated a low level of evidence for CEJ in improving leukocyte elevation efficacy, KPS levels, and myelosuppressive toxicity. Therefore, large-scale, high-quality, rigorous multicenter double-blind controlled trials are recommended to strengthen the evidence level.

Key words： nonprescription drugs; leukopenia; safety; treatment outcome; GRADE approach; Meta-analysis; Compound E’jiao Jiang

Cite this article

Zhenkai LU , Chang TAN , Yingjie ZHI , Xuming ZHANG , Yanming XIE . Efficacy and safety of Compound E’jiao Jiang (复方阿胶浆) for treating leukopenia based: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2025 , 45(5) : 941 -953 . DOI: 10.19852/j.cnki.jtcm.2025.05.001

References

1. Chinese Association of Integrated Traditional Chinese and Western Medicine Hematology Professional Committee. Expert consensus on integrated Traditional Chinese and Western Medicine treatment for leukopenia after tumor radiotherapy and chemotherapy. Zhong Guo Zhong Liu Fang Zhi Za Zhi 2022; 29: 1641-6+52.
2. Tian SD, Dong Q, Qi S, et al. Expert consensus on Traditional Chinese Medicine prevention and evaluation of leukopenia after chemotherapy. Xian Dai Zhong Yi Lin Chuang 2018; 25: 1-6.
3. Li J, Tao WL, Wei SD, et al. Safety and clinical evaluation of recombinant human granulocyte colony-stimulating factor (rhG-CSF). Zhong Guo Yi Yuan Yong Yao Ping Jia Yu Fen Xi 2008; 12: 484-6.
4. Pfister D, Ang K, Brizel D. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Asian J Androl 2018; 20: 4-7.
5. Qi XT, Zhang JX, Zhang XL, et al. Research progress on Traditional Chinese Medicine treatment for leukopenia induced by chemotherapy. Zhong Cao Yao 2019; 50: 5088-95.
6. Tian H, Wei Q, Wu W, et al. Effects of Traditional Chinese Medicine on chemotherapy-induced myelosuppression and febrile neutropenia in breast cancer patients. Evid Based Complement Alternat Med 2015; 20: 1-11.
7. WHO international standard terminologies on Traditional Chinese Medicine. Geneva: World Health Organization 2022; Licence: CC BY-NC-SA 3.0 IGO.
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: 71.
9. National Standard of Traditional Chinese Medicine in the People's Republic of China. Diagnostic criteria and efficacy standards for Traditional Chinese Medicine syndromes. Nanjing: Nanjing University Publishing House, 1994: 1-31.
10. National Health Commission of the People's Republic of China. Guidelines for clinical application of novel antitumor drugs. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi 2020; 6: 16-47.
11. Zhang S, Liang F, Tannock I. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer 2016; 16: 392-8.
12. World Health Organization. Grading criteria for acute and subacute toxicity reactions of anticancer drugs. Cancer 1992; 11: 2.
13. Propadalo I, Tranfic M, Vuka I, Barcot O, Pericic TP, Puljak L. In Cochrane reviews, risk of bias assessments for allocation concealment were frequently not in line with Cochrane's Handbook guidance. J Clin Epidemiol 2019; 106: 10-7.
14. Fu L, Fu H, Liu LQ, et al. Efficacy of compound gelatin syrup on myelosuppression induced by the combination of gemcitabine and cisplatin regimen. Lin Chuang Zhong Liu Xue Za Zhi 2014; 19: 739-42.
15. Liu ZH, Shi JW. Clinical observation of compound gelatin syrup in enhancing efficacy and reducing toxicity of chemotherapy for lung cancer. Zhong Hua Zhong Yi Yao Xue Kan 2007; 11: 2427-9.
16. Lu DR, Lu DX, Yin YK, et al. Clinical study of compound gelatin syrup improving quality of life in patients with malignant tumors. Yunnan Zhong Yi Zhong Yao Za Zhi 2015; 36: 14-7.
17. Zhou Y. The effectiveness of compound gelatin syrup in preventing chemotherapy-induced hematological abnormalities. Shandong: Shandong University, 2013: 1-52.
18. Zhou Y, Hou HY, Xu Y, et al. Effects of compound gelatin syrup on chemotherapy-induced myelosuppression in small cell lung cancer. Shandong Da Xue Xue Bao (Medical Edition) 2018; 56: 14-7.
19. Zhou XT, Shen J. Clinical observation on the treatment of leukopenia after paclitaxel and platinum chemotherapy for malignant tumors with Compound Ejiao Syrup. China Association for the Promotion of Traditional Chinese Medicine Research:Proceedings of the 1st National Symposium on Specialty and Disease Construction; 2014 Oct 31; Henan, China. Beijing: China Association for Promotion of Traditional Chinese Medicine Research, 2014: 385-7.
20. Song T, Liang SP, Wang HQ, et al. Clinical efficacy observation of compound gelatin syrup in improving chemotherapy-induced myelosuppression. Tianjin Yi Ke Da Xue Xue Bao 2016; 12: 24-7.
21. Zhang GZ, Chen HT. Clinical study of compound gelatin syrup and recombinant human erythropoietin in improving chemotherapy-related anemia. Xin Zhong Yi 2017; 49: 123-6.
22. Zhang YH, Li YX, Li Y. Clinical observation of compound gelatin syrup on chemotherapy-induced leukopenia in malignant tumors. Zhong Guo Dang Dai Yi Yao 2010; 17: 77-8.
23. Zhang CH, Wang HJ, Zhang ZH. Comparative study of compound gelatin syrup with squalene and vitamin B4 in the treatment of clozapine-induced leukopenia. Shan Dong Jing Shen Yi Xue 2002; 15: 147-8.
24. Li HB, Zhou QM. Effects of compound gelatin syrup combined with personalized comprehensive nursing on chemotherapy-induced myelosuppression and cancer-related fatigue in cervical cancer. Zhong Guo Zhong Liu Lin Chuang Yu Kang Fu 2017; 24: 884-7.
25. Li ZB, Jiu SW. Treatment of leukopenia caused by Sjogren's syndrome with compound gelatin syrup:a report of 50 cases. Zhong Guo Min Jian Liao Fa 2016; 24: 71-2.
26. Li N. Clinical observation of compound gelatin syrup in the treatment of cancer-related fatigue. Beijing: Beijing University of Chinese Medicine, 2012: 1-42.
27. Yang KP, Li ZB, Wang XC, et al. Clinical study of compound gelatin syrup in the treatment of Sjogren's syndrome with leukopenia. Proceedings of the 13th National Conference on Rheumatology; 2015 Oct 30; Hangzhou, China. Beijing: Chinese Medical Association, Rheumatology Society, 2015: 37-9.
28. Bu YQ, Zang YQ, He LY, et al. Clinical observation of compound gelatin syrup combined with XELOX regimen in the treatment of advanced gastric cancer. Xian Dai Zhong Xi Yi Jie He Za Zhi 2013; 22: 4013-14.
29. Xu NW, Chen HX, Li LJ, et al. Clinical observation of compound gelatin syrup in preventing and treating chemotherapy-related leukopenia in B-cell lymphoma. Quan Ke Yi Xue Lin Chuang Yu Jiao Yu 2014; 6: 677-9.
30. Tan QX, Long D, Zhou MQ. Application of compound gelatin syrup in chemotherapy of cancer patients. Xian Dai Zhong Xi Yi Jie He Za Zhi 2009; 18: 4502-3.
31. Zhao JL, Zhao YM, Xu H, et al. Thirty cases of compound gelatin syrup combined with chemotherapy in the treatment of advanced gynecological tumors. Proceedings of the 11th National Conference on Traditional Chinese Medicine Gynecology; 2011 Oct 9-10; Henan, China. Beijing: Gynecology Branch of China Association of Chinese Medicine, 2011: 386-7.
32. Lu JJ, Ling L, Yan XX. Clinical treatment of leukopenia induced by cyclophosphamide in lupus nephritis. Zhong Guo Zhong Xi Yi Jie He Shen Bing Za Zhi 2002; 3: 478.
33. Shao YY, Liu PM. Clinical observation of compound gelatin syrup on bone marrow protection in patients with breast cancer after chemotherapy. Zhong Guo Yi Xue Dao Bao 2009; 6: 161-4.
34. Min XM. Clinical observation of compound gelatin syrup combined with leukocyte elevating tablets in the treatment of leukopenia after tumor chemotherapy. Yi Xue Qian Yan 2012; 7: 33.
35. Chen M, Shen J, Zhou XT, et al. Clinical observation of compound gelatin syrup combined with licorice tablets in the treatment of leukopenia after chemotherapy for malignant tumors. Shi Yong Zhong Yi Yao Za Zhi 2015; 13: 406.
36. Gu YF, Zhang YC, Shi J, et al. Clinical observation of compound gelatin syrup in preventing and treating leukopenia after chemotherapy in gastric cancer patients. Huan Qiu Zhong Yi Yao 2012; 5: 614-6.
37. Gu YF, Zhang YC, Shi J, et al. Clinical observation of compound gelatin syrup on peripheral blood protection in chemotherapy patients. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2012; 19: 69-71.
38. Wei YS, Wang BL, Zhang JH, et al. Observation on the efficacy of compound gelatin syrup combined with chemotherapy in the treatment of advanced colorectal cancer. Xian Dai Zhong Xi Yi Jie He Za Zhi 2017; 26: 3912-4.
39. Huang ZH, Jiang YL, Han F, et al. Observation on the effect of compound gelatin syrup in preventing chemotherapy-induced blood count decline. Lin Chuang He Li Yong Yao Za Zhi 2016; 9: 5-6.
40. Li MC, Liao JH, Lu ZH, et al. Clinical observation of compound gelatin syrup combined with EP regimen chemotherapy in extensive-stage small cell lung cancer. Gan Nan Yi Xue Yuan Xue Bao 2019; 39: 129-31.
41. Long D, Tan QX, Liang RM, et al. The role of compound gelatin syrup in chemotherapy for malignant tumors. Proceedings of the 5th International Symposium on Traditional Chinese Medicine and Integrated Chinese and Western Medicine for Oncology & The 14th National Conference on Oncology in Chinese Medicine; 2014 Jul 18; Guangzhou, China. Beijing: Oncology Branch of China Association of Chinese Medicine, 2014: 602-4.
42. Huang X, Wang QH, Wang DS, et al. Comparative study of the effect of prepared rehmannia liquid extract and its powder on peripheral blood in mice. Zhong Cheng Yao 2002; 7: 111-9.
43. Chen HH, You JH, Tian SS, et al. Pharmacological and clinical research overview of compound gelatin syrup. Zhong Guo Zhong Yao Za Zhi 2012; 37: 3021-3.
44. Zhang D, Hou L, Sun T, et al. Clinical study of compound gelatin syrup in improving chemotherapy-related anemia. Beijing Zhong Yi Yao Da Xue Xue Bao 2012; 19: 15-8.
45. Li H, Zhang RR. Analysis of medication rules for treating leukopenia with Traditional Chinese Medicine compound prescriptions. Zhong Yi Za Zhi 2015; 56: 338-41.
46. Li CR, Zhu XY. Summary of Traditional Chinese Medicine treatment for leukopenia. Zhong Guo Liao Yang Yi Xue 2008; 17: 636-8.
47. Zhang M, Tian SD, Liu L, et al. Analysis of constitution characteristics of malignant tumor patients and constitution reasons for leukopenia after chemotherapy. Jilin Zhong Yi Yao 2017; 37: 14-8.
48. Xu HY, Wang SS, Yang HJ, et al. Study on the mechanism of compound gelatin syrup in adjuvant treatment of tumors based on network pharmacology. Zhong Guo Zhong Yao Za Zhi 2014; 39: 3148-51.
49. Bai X, Lu M. Review of Traditional Chinese Medicine prevention and treatment of leukopenia after chemotherapy. Xinjiang Zhong Yi Yao 2021; 39: 105-7.
50. Wang X. The reason for the 21-day cycle of chemotherapy. Ren Ren Jian Kang 2021; 3: 48-9.
51. Li M, Ma HY, Shen JD, et al. Synergistic and detoxifying effects of compound gelatin syrup on 5-FU chemotherapy in H22 hepatocellular carcinoma-bearing mice. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2012; 18: 216-9.
52. Xu RR, Liu HL, Hu QY, et al. Safety observation of compound gelatin syrup in the treatment of anemia. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2013; 19: 315-8.
53. Xu W, Liu XH, Chen G, et al. Discussion on the regulatory effect of ‘Shaoyang Chunsheng Qi’ theory on hematopoietic function in mice after radiotherapy from the perspective of liver-blood regulation. Shi Zhen Guo Yi Guo Yao 2016; 27: 45-6.
54. Yao JH, Tian ZY, Zhao SF, et al. Clinical observation of Shengbai capsules in the treatment of leukopenia. Xi Bu Zhong Yi Yao 2014; 27: 94-6.
Options
Outlines

/

〈 〉